Loading
Life sciences · Journal article
Journal of Ethnopharmacology · July 29, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical mechanistic study demonstrating that 1-deoxynojirimycin (DNJ) attenuates features of diabetic cardiomyopathy in cultured cardiomyocytes and db/db mice, apparently via PI3K/AKT-mediated mitochondrial protection and reduced apoptosis. The authors present this as preliminary evidence suitable for hypothesis generation, not as a ready-to-test clinical intervention.
In vitro cell culture study combined with db/db mouse model. Rat ventricular myoblasts (H9C2 cell line) exposed to high glucose; db/db mice (genetic model of type 2 diabetes and obesity).. Intervention: 1-Deoxynojirimycin (DNJ), a naturally occurring α-glucosidase inhibitor from mulberry leaves, administered by gavage to mice or added to cell culture.. Compared with: High-glucose conditions in H9C2 cells without DNJ; db/db mice not specified to have a vehicle or untreated control in the abstract. PI3K/AKT pathway inhibitors used to verify mechanism..
DNJ lowered body weight and fasting blood glucose levels in db/db mice DNJ enhanced glucose tolerance and cardiac performance in db/db mice DNJ reduced myocardial fibrosis, hypertrophy, and lipid accumulation in db/db mice
No data on adverse effects or pharmacokinetics in the abstract.
The results do not provide direct clinical evidence and should be read as foundational mechanistic work that could guide future translational studies in diabetic cardiomyopathy. Human trials would be needed to establish whether DNJ has clinical utility.
Early mechanistic study combining in vitro and animal models with pathway inhibitor validation, but lacking human clinical data and using surrogate endpoints of cardiac function and cell viability.
As stated by the source record.
The results do not provide direct clinical evidence and should be read as foundational mechanistic work that could guide future translational studies in diabetic cardiomyopathy. Human trials would be needed to establish whether DNJ has clinical utility.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Ethnopharmacological relevance. 1-Deoxynojirimycin (DNJ), a naturally occurring alkaloid derived from mulberry leaves (Morus alba L.), is a powerful α-glucosidase inhibitor that has notable hypoglycemic effects. Nonetheless, the fundamental molecular mechanisms-especially diabetic cardiomyopathy (DCM)-are still not fully understood.Purpose. This study sought to determine the cardioprotective effect of DNJ in diabetic cardiomyopathy and to elucidate the associated molecular mechanism.Methods. A high glucose-induced DCM model was established in H9C2 cells and db/db mice. DNJ was administered by gavage or coculture with cells. The molecular mechanism of DNJ activity and changes in the activity of the PI3K/AKT pathway were evaluated by echocardiography, tissue staining, transmission electron microscopy, fluorescence probes, biochemical kits, Western blotting, and transcriptome sequencing, and the pathway was verified by the use of inhibitors.Results. In vivo tests initially demonstrated that DNJ may lower body weight and fasting blood glucose levels; enhance glucose tolerance and cardiac performance; diminish myocardial fibrosis, myocardial hypertrophy, and lipid accumulation; and reduce myocardial cell death in db/db mice. DNJ therapy improved the HG-induced reduction in H9C2 cell viability, reduced ROS levels, mitigated oxidative damage, and inhibited cell death. DNJ can restore HG-mediated suppression of ATP5B expression and ATP levels, potentially enhancing mitochondrial energy utilization. The therapeutic efficacy of DNJ may be contingent upon the PI3K/AKT pathway, underscoring its regulatory significance, particularly in mediating cellular responses to oxidative stress and promoting cell survival in H9C2 cells.Conclusions. Our preliminary findings suggest that DNJ may alleviate diabetic myocardial injury, possibly by triggering the PI3K/AKT pathway. This work offers a preliminary rationale for DNJ as a prospective treatment agent for DCM.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.